当前位置: 首页 >> 检索结果
共有 2436 条符合本次的查询结果, 用时 3.0631253 秒

281. Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.

作者: David J Lederer.;Williamson Z Bradford.;Elizabeth A Fagan.;Ian Glaspole.;Marilyn K Glassberg.;Kenneth F Glasscock.;David Kardatzke.;Talmadge E King.;Lisa H Lancaster.;Steven D Nathan.;Carlos A Pereira.;Steven A Sahn.;Jeffrey J Swigris.;Paul W Noble.
来源: Chest. 2015年148卷1期196-201页
FVC outcomes in clinical trials on idiopathic pulmonary fibrosis (IPF) can be substantially influenced by the analytic methodology and the handling of missing data. We conducted a series of sensitivity analyses to assess the robustness of the statistical finding and the stability of the estimate of the magnitude of treatment effect on the primary end point of FVC change in a phase 3 trial evaluating pirfenidone in adults with IPF.

282. The Adult Calfactant in Acute Respiratory Distress Syndrome Trial.

作者: Douglas F Willson.;Jonathon D Truwit.;Mark R Conaway.;Christine S Traul.;Edmund E Egan.
来源: Chest. 2015年148卷2期356-364页
Surfactant has been shown to be dysfunctional in ARDS, and exogenous surfactant has proven effective in many forms of neonatal and pediatric acute lung injury (ALI). In view of the positive results of our studies in children along with evidence that surfactant-associated protein B containing pharmaceutical surfactants might be more effective, we designed a multiinstitutional, randomized, controlled, and masked trial of calfactant, a calf lung surfactant, in adults and children with ALI/ARDS due to direct lung injury.

283. Relapse in FEV1 Decline After Steroid Withdrawal in COPD.

作者: Lisette I Z Kunz.;Dirkje S Postma.;Karin Klooster.;Thérese S Lapperre.;Judith M Vonk.;Jacob K Sont.;Huib A M Kerstjens.;Jiska B Snoeck-Stroband.;Pieter S Hiemstra.;Peter J Sterk.; .
来源: Chest. 2015年148卷2期389-396页
We previously observed that 30 months of inhaled corticosteroid (ICS) treatment can attenuate FEV1 decline in COPD, but it is unclear whether withdrawal induces a relapse. We hypothesized that FEV1 decline, airway hyperresponsiveness (AHR), and quality of life (QOL) deteriorate after ICS cessation even after prolonged use.

284. Prognosis for Spontaneous Resolution of OSA in Children.

作者: Ronald D Chervin.;Susan S Ellenberg.;Xiaoling Hou.;Carole L Marcus.;Susan L Garetz.;Eliot S Katz.;Elise K Hodges.;Ron B Mitchell.;Dwight T Jones.;Raanan Arens.;Raouf Amin.;Susan Redline.;Carol L Rosen.; .
来源: Chest. 2015年148卷5期1204-1213页
Adenotonsillectomy (AT) is commonly performed for childhood OSA syndrome (OSAS), but little is known about prognosis without treatment.

285. An Internet-Mediated Pedometer-Based Program Improves Health-Related Quality-of-Life Domains and Daily Step Counts in COPD: A Randomized Controlled Trial.

作者: Marilyn L Moy.;Riley J Collins.;Carlos H Martinez.;Reema Kadri.;Pia Roman.;Robert G Holleman.;Hyungjin Myra Kim.;Huong Q Nguyen.;Miriam D Cohen.;David E Goodrich.;Nicholas D Giardino.;Caroline R Richardson.
来源: Chest. 2015年148卷1期128-137页
Low levels of physical activity (PA) are associated with poor outcomes in people with COPD. Interventions to increase PA could improve outcomes.

286. A Randomized Trial of 1% vs 2% Lignocaine by the Spray-as-You-Go Technique for Topical Anesthesia During Flexible Bronchoscopy.

作者: Harpreet Kaur.;Sahajal Dhooria.;Ashutosh N Aggarwal.;Dheeraj Gupta.;Digambar Behera.;Ritesh Agarwal.
来源: Chest. 2015年148卷3期739-745页
The optimal concentration of lignocaine to be used during flexible bronchoscopy (FB) remains unknown. This randomized controlled trial compared the efficacy and safety of 1% and 2% lignocaine solution for topical anesthesia during FB.

287. Effects of weight loss on airway responsiveness in obese adults with asthma: does weight loss lead to reversibility of asthma?

作者: Smita Pakhale.;Justine Baron.;Robert Dent.;Katherine Vandemheen.;Shawn D Aaron.
来源: Chest. 2015年147卷6期1582-1590页
The growing epidemics of obesity and asthma are major public health concerns. Although asthma-obesity links are widely studied, the effects of weight loss on asthma severity measured by airway hyperresponsiveness (AHR) have received limited attention. The main study objective was to examine whether weight reduction reduces asthma severity in obese adults with asthma.

288. A Randomized Controlled Study to Examine the Effect of a Lifestyle Modification Program in OSA.

作者: Susanna S S Ng.;Ruth S M Chan.;Jean Woo.;Tat-On Chan.;Bernice H K Cheung.;Mandy M M Sea.;Kin-Wang To.;Ken K P Chan.;Jenny Ngai.;Wing-Ho Yip.;Fanny W S Ko.;David S C Hui.
来源: Chest. 2015年148卷5期1193-1203页
Obesity is an important risk factor for OSA. This study aimed to assess the effect of weight reduction through a lifestyle modification program (LMP) on patients with moderate to severe OSA.

289. A randomized controlled trial comparing the ventilation duration between adaptive support ventilation and pressure assist/control ventilation in medical patients in the ICU.

作者: Cenk Kirakli.;Ilknur Naz.;Ozlem Ediboglu.;Dursun Tatar.;Ahmet Budak.;Emel Tellioglu.
来源: Chest. 2015年147卷6期1503-1509页
Adaptive support ventilation (ASV) is a closed loop mode of mechanical ventilation (MV) that provides a target minute ventilation by automatically adapting inspiratory pressure and respiratory rate with the minimum work of breathing on the part of the patient. The aim of this study was to determine the effect of ASV on total MV duration when compared with pressure assist/control ventilation.

290. Standardizing Predicted Body Weight Equations for Mechanical Ventilation Tidal Volume Settings.

作者: Olinto Linares-Perdomo.;Thomas D East.;Roy Brower.;Alan H Morris.
来源: Chest. 2015年148卷1期73-78页
Recent recommendations for lung protective mechanical ventilation include a tidal volume target of 6 mL/kg predicted body weight (PBW). Different PBW equations might introduce important differences in tidal volumes delivered to research subjects and patients.

291. Lung Volume Reduction in Emphysema Improves Chest Wall Asynchrony.

作者: Zaid Zoumot.;Antonella LoMauro.;Andrea Aliverti.;Christopher Nelson.;Simon Ward.;Simon Jordan.;Michael I Polkey.;Pallav L Shah.;Nicholas S Hopkinson.
来源: Chest. 2015年148卷1期185-195页
Lung volume reduction (LVR) techniques improve lung function in selected patients with emphysema, but the impact of LVR procedures on the asynchronous movement of different chest wall compartments, which is a feature of emphysema, is not known.

292. Acute effect of an inhaled glucocorticosteroid on albuterol-induced bronchodilation in patients with moderately severe asthma.

作者: Eliana S Mendes.;Lilian Cadet.;Johana Arana.;Adam Wanner.
来源: Chest. 2015年147卷4期1037-1042页
We have previously shown that in patients with asthma a single dose of an inhaled glucocorticosteroid (ICS) acutely potentiates inhaled albuterol-induced airway vascular smooth muscle relaxation through a nongenomic action. An effect on airway smooth muscle was not seen, presumably because the patients had normal lung function. The purpose of the present study was to conduct a similar study in patients with asthma with airflow obstruction to determine if an ICS could acutely also potentiate albuterol-induced airway smooth muscle relaxation in them.

293. Talc pleurodesis through indwelling pleural catheters for malignant pleural effusions: retrospective case series of a novel clinical pathway.

作者: Liju Ahmed.;Hugh Ip.;Deepak Rao.;Nishil Patel.;Farinaz Noorzad.
来源: Chest. 2014年146卷6期e190-e194页
Malignant pleural effusions cause significant morbidity, but there is no gold standard minimally invasive treatment. A new therapeutic approach combines talc pleurodesis and indwelling pleural catheters (IPCs) to enable outpatient management. This case series summarizes the safety and efficacy data of all patients (24) with a symptomatic malignant pleural effusion who underwent talc pleurodeses via IPCs between December 2010 and July 2013. Successful pleurodesis was achieved in 22 procedures (92%). There was one empyema, one hydropneumothorax, one recurrent effusion, and two minor complications: one drain site wound infection and one complaint of chest pain. Twenty-two procedures (92%) were performed in the outpatient setting. This report confirms the safety and efficacy of administering talc slurry through IPCs in an outpatient setting. Studies in a larger cohort are necessary to define the role of this novel approach in the treatment algorithm of patients with this condition.

294. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD.

作者: James F Donohue.;Nicola A Hanania.;Barry Make.;Matthew C Miles.;Donald A Mahler.;Lisa Curry.;Robert Tosiello.;Alistair Wheeler.;Donald P Tashkin.
来源: Chest. 2014年146卷6期1531-1542页
Arformoterol tartrate (arformoterol, 15 μg bid) is a nebulized long-acting β2-agonist approved for maintenance treatment of COPD.

295. Percutaneous dilatational tracheostomy with a double-lumen endotracheal tube: a comparison of feasibility, gas exchange, and airway pressures.

作者: Maria Vargas.;Paolo Pelosi.;Gaetano Tessitore.;Fulvio Aloj.;Iole Brunetti.;Enrico Arditi.;Dorino Salami.;Robert M Kacmarek.;Giuseppe Servillo.
来源: Chest. 2015年147卷5期1267-1274页
Gas exchange and airway pressures are markedly altered during percutaneous dilatational tracheostomy (PDT). A double-lumen endotracheal tube (DLET) has been developed for better airway management during PDT. The current study prospectively evaluated the in vivo feasibility, gas exchange, and airway pressures during PDT with DLET compared with a conventional endotracheal tube (ETT).

296. Exaggerated pulmonary hypertension and right ventricular dysfunction in high-altitude dwellers with patent foramen ovale.

作者: Roman Brenner.;Lorenza Pratali.;Stefano F Rimoldi.;Carla Ximena Murillo Jauregui.;Rodrigo Soria.;Emrush Rexhaj.;Carlos Salinas Salmón.;Mercedes Villena.;Catherine Romero.;Claudio Sartori.;Yves Allemann.;Urs Scherrer.
来源: Chest. 2015年147卷4期1072-1079页
There is considerable interindividual variability in pulmonary artery pressure among high-altitude (HA) dwellers, but the underlying mechanism is not known. At low altitude, a patent foramen ovale (PFO) is present in about 25% of the general population. Its prevalence is increased in clinical conditions associated with pulmonary hypertension and arterial hypoxemia, and it is thought to aggravate these problems.

297. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort.

作者: Hana Müllerova.;Diego J Maselli.;Nicholas Locantore.;Jørgen Vestbo.;John R Hurst.;Jadwiga A Wedzicha.;Per Bakke.;Alvar Agusti.;Antonio Anzueto.
来源: Chest. 2015年147卷4期999-1007页
Exacerbations of COPD requiring hospital admission have important clinical and societal implications. We sought to investigate the incidence, recurrence, risk factors, and mortality of patients with COPD exacerbations requiring hospital admission compared with those without hospital admission during 3-year follow-up. Patients with COPD (N = 2,138) were identified from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) observational cohort.

298. Family-based psychosocial support and education as part of pulmonary rehabilitation in COPD: a randomized controlled trial.

作者: Alda Marques.;Cristina Jácome.;Joana Cruz.;Raquel Gabriel.;Dina Brooks.;Daniela Figueiredo.
来源: Chest. 2015年147卷3期662-672页
Involving family as part of the patient's rehabilitation plan of care might enhance the management of COPD. The primary aim of this study was to investigate the impact of a family-based pulmonary rehabilitation (PR) program on patients and family members' coping strategies to manage COPD.

299. Quality of well-being outcomes in the National Emphysema Treatment Trial.

作者: Robert M Kaplan.;Qiankun Sun.;Andrew L Ries.
来源: Chest. 2015年147卷2期377-387页
Surgical and medical treatments for emphysema may affect both quality and quantity of life. The purpose of this article is to report outcomes from the National Emphysema Treatment Trial (NETT) using an index that combines quality and quantity of life.

300. Isoniazid-associated hepatitis in adults infected with HIV receiving 36 months of isoniazid prophylaxis in Botswana.

作者: Zegabriel Tedla.;Minh-Ly Nguyen.;Thabisa Sibanda.;Samba Nyirenda.;Tefera B Agizew.;Sonali Girde.;Charles E Rose.;Taraz Samandari.
来源: Chest. 2015年147卷5期1376-1384页
The World Health Organization recommends 36 months of isoniazid preventive therapy (36IPT) for adults infected with HIV living in TB-endemic countries. We determined the rates and risk factors for isoniazid-associated hepatitis with the use of 36IPT.
共有 2436 条符合本次的查询结果, 用时 3.0631253 秒